BMY Q1 2017 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q1 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$4.9B+12.3% YoY

Gross Profit

$3.7B75.3% margin

Operating Income

$1.6B32.8% margin

Net Income

$1.6B31.9% margin

EPS (Diluted)

$0.94

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

$861M

Free Cash Flow

$570M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$32.9B

Total Liabilities

$18.4B

Stockholders' Equity

$14.4B

Cash & Equivalents

$3.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.9B	$4.4B	+12.3%
Gross Profit	$3.7B	$3.3B	+11.1%
Operating Income	$1.6B	$1.1B	+45.1%
Net Income	$1.6B	$1.2B	+31.7%

Revenue Segments

Opdivo

$1.1B23%

Eliquis

$1.1B22%

Orencia

$535M11%

Mature Products And All Other

$499M10%

Sprycel

$463M9%

Yervoy

$330M7%

Baraclude

$282M6%

Reyataz

$193M4%

Sustiva Franchise

$184M4%

Hepatitis C Portfolio

$162M3%

Empliciti

$53M1%